1 / 63

Imtiaz Ahmad, MD, FCCP 21 st Century Oncology

Lee Health Medical Grand Round. If You Can’t Breathe, Nothing Else Matters Myths and Facts about Managing Patients with Respiratory Failure lungcare.net/medical-grand-rounds/. Imtiaz Ahmad, MD, FCCP 21 st Century Oncology. Acknowledgement. Ruth Milien Jonathas, ARNP

jword
Download Presentation

Imtiaz Ahmad, MD, FCCP 21 st Century Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lee Health Medical Grand Round If You Can’t Breathe, Nothing Else Matters Myths and Facts about Managing Patients with Respiratory Failure lungcare.net/medical-grand-rounds/ Imtiaz Ahmad, MD, FCCP 21st Century Oncology

  2. Acknowledgement • Ruth Milien Jonathas, ARNP • Bindu Asok Kumar, ARNP

  3. Smoking Cessation is the Key! • Prevention of smoking remains to be the key to reduce the risk of pulmonary diseases

  4. Disclosure None

  5. Learning objectives • Pneumonia, asthma, and COPD are common etiologic factors for respiratory failure. Explain pathophysiology and critical management issues in both inpatient and outpatient setting. • Discuss myths and facts surrounding the length of stay, re-admission, and quality of life of patients with respiratory failure.

  6. Key Points • Acute respiratory failure :Why it matters • Common etiology • NIV: Management principles • COPD / Asthma: Myths/Facts • Common issues • Re-admission and transitional care • Home oxygen • OSA screening

  7. $30,210,000,000

  8. Respiratory failure • Failure of lung to meet metabolic demands • PaO2<60 mm or PaCO2>50 mm or PaO2/FiO2≤200 • Oxygenation vs ventilation failure

  9. Respiratory Failure • Hospitalization for ARF 1.9 million • Mortality 21% (4th leading cause) • LOS 7.1 days • Mean cost per case $15,900 • Age • >=65 yrs : 59% • 45-65 yrs: 31%

  10. Respiratory Failure • Etiology • Pneumonia- 46% • CHF - 37% • COPD/Asthma 35% • Sepsis 21% • ARDS - 16% • Ventilation • Mechanical : 42% • Non-invasive 10% • Mortality 21% Proportion of patients with acute respiratory failure with the 5 most common medical conditions from 2001 to 2009.

  11. Respiratory Failure : A Case for NIV • 74 y WM with AMS, SOB with 2-3 hr, ? benzodiazepine for anxiety prior to transfer to ER • PMH :COPD, HTN, DM, CKD, AF, Cardiomyopathy • Ex-smoker 25 PY • VS: BP111/89, HR 96/min, RR 24/min, O2 sat 100% (FIO2 100%), T 96.7 • PE: • Morbidly obese, unresponsive, tachypneic, ↑ WOB, BS diminished, edema 2+, chronic skin changes in LE • JVD neg, no focal deficit • Lab: WBC 5.1, Hb 9, CO2>40, BUN/Cr 38/1.2, BNP 6230↑,trop NA • Echo : EF 55%, RVSP 48, LV dilated, LAE, LVH

  12. Respiratory Failure : A Case for NIV • ABG#1: (100%) 7.19/139/392/98% • Baseline ABG: (36%) 7.34/58/73/94% • BPAP 15/5, FIO2 50% started • ABG#2 (1913 hr): (50%) 7.22/121/170/98% (MS improving, barely responsive) • RX bronchodilator, IV steroid, antibiotics • ABG#3 (0318hr): (35%) 7.33/78/94/96% • BPAP changed to O2 3LNC at 6AM • ABG on D/C day (RA) 7.48/48/56/91%

  13. Respiratory Failure : A Case for NIV

  14. Respiratory Failure : A Case for NIV • Discharge diagnosis: • Acute on chronic respiratory failure • COPD exacerbation • OSA/OHS (clinical) • Pulmonary edema due to diastolic CHF • Pulmonary hypertension

  15. Respiratory Failure : Myths & Facts about NIV • Learning points: • Patient selection (hypercapnic COPD exac, pulm edema) • Trial of NIPPV worthwhile if there is no need for emergent intubation • Close monitoring (Clinical/ABG) • Hypercapnic encephalopathy is not a contraindication • MS should improve by 1-2 hr • Early intubation, • if no improvement in ABG • Hemodynamically unstable • Sepsis • AMI

  16. Respiratory Failure: NIV vs MV 45 mm Hg 40 mm Hg 60 mm Hg

  17. NIV: Failure to watch • No improvement of O2/CO2 in 2 hours • Worsening tachypnea or increased WOB • Declining mental status or agitation • Inability to clear secretions • Intolerance of mask or ventilator

  18. NIV: Monitoring by Numbers

  19. NIV: CPAP vs BPAP

  20. NIV : Options • CPAP • CHF/OSA/PNA/ARDS • Setting: APAP 5-15 cm • BiPAP • COPD/Asthma/PNA/ARDS • Setting: 10/5 cm, titrate for TV/PO2/PCo2 • Max IPAP/EPAP: 25/15 cm • Backup rate 12-16/min • Titrate IPAP by 2 cm for hypercapnia • Titrate IPAP/EPAP by 2 cm for hypoxia

  21. NIV : AVAPS

  22. NIV : Options • AVAPS • Adjust PS to guarantee an average tidal volume. • COPD/OHS/Restrictive lung disease • Setting • Tidal volume: 8 ml/kg (IBW) • IPAPmax: 25-50 cm, IPAPmin : EPAP + 4 cm • EPAP : 6 cm • Rate : 8-12 BPM (2 below resting rate) • I-Time: 1.5 sec (patient comfort) • Rise time : 2 sec (patient comfort) • Monitor : PO2/PCo2/O2 sat

  23. Evidence for efficacy and strength of recommendation: Noninvasive ventilation in acute respiratory failureNicholas S. Hill, MD; John Brennan, MD; Erik Garpestad, MD; Stefano Nava, MD 2007 Strength of Recommendation Recommended: first choice for ventilatory support in selected patients Guideline:can be used in appropriate patients but careful monitoring advised Option: suitable for a very carefully selected and monitored minority of patients. Level of evidence A: multiple randomized controlled trials and meta-analyses B: more than one randomized, controlled trial, case control series, or cohort studies C: case series or conflicting data

  24. NIV in ARF: Hi Flow Nasal Cannula (HFNC) • MECHANISMS • Warming and humidification of secretions. • Washout of nasopharyngeal dead space • CPAP effect • Accurate delivery of oxygen • Decreased inspiratory effort

  25. NIV in ARF: Hi Flow Nasal Cannula (HFNC)

  26. NIV in ARF: Hi Flow Nasal Cannula (HFNC) • Setting • Flow rate: 20 to 35 L/minute (range 5 to 60 L/minute) • FIO2: 40% (set to target a desired peripheral oxygen saturation) • Downgrade to low-flow nasal cannulae • flow rate ≤20 L/minute and FiO2 ≤35 percent. • Outcome: No improvement in clinically meaningful outcomes • Contraindication: • Abnormalities or surgery of the face, nose, or airway

  27. ARF : NIV-Heliox • Heliox: helium 79% and oxygen 21% • Lower Density (6x) • Indication • Upper airway obstruction • COPD/asthma exac • VCD • Respiratory failure • Benefits • improves air flow by transforming turbulent flow into laminar flow.

  28. Myths vs Facts

  29. Myths vs Facts: Oxygen Therapy in COPD Myths Facts • Oxygen therapy in COPD exacerbation cause hypoventilation leading to hypercapnia • Not everyone • Etiology is unclear • VQ mismatch • Haldane effect • ?Hypoventilation • Excessive O2 therapy leads to poor outcome • Goal: Titrated O2 therapy O2 sat 88-92%

  30. Myths vs Facts : Oxygen helps COPD patient live longer Yes No

  31. Myths vs Facts : COPD is same as Asthma

  32. Myths vs Facts : COPD is same as Asthma COPD Anti-inflammatory Rx • Steroid • Azithromycin • Roflumilast (PDE4 Inhibitor) • Statin

  33. Myths vs Facts : COPD is same as Asthma Asthma Anti-inflammatory Rx • Steroid • Leukotriene modifiers • Mast cell stabilizers • Anti-IL5 (mepolizumab/benralizumab) • Anti-IL4 (Dupilumab) • ?Bronchial thermoplasty

  34. Facts vs Myth Facts Myths • IV and oral steroids are equally effective for COPD exacerbation • IV steroids are more effective

  35. Facts vs Myth Facts Myths • Bronchoscopy has no role in COPD exacerbation • Bronchoscopy improves patient’s dyspnea, wheezing and shortens the LOS

  36. Myth vs Facts Myths Facts • Patient does not need steroid if there is no ‘wheezing’ • Steroid is effective in COPD exacerbation • Treatment failure • Improve FEV1 • Improve PaO2

  37. Common Issues to Consider

  38. COPD: When to Admit • Admission criteria • Acute respiratory failure • Failure of outpatient rx for COPD • Comorbidities (PNA, organ failure) • Unexplained symptoms (AMS, anorexia) • ICU admission criteria • Severe dyspnea • MS changes • Hypoxia/acidosis despite NIV • Hemodynamic instability/organ failure

  39. COPD: Readmission & Prevention Risk for Readmission Intervention

  40. COPD/Asthma: Other Discharge Considerations • Early ambulation • Home oxygen evaluation • Steroid for 2-3 weeks • Anti-inflammatory Rx (azithromycin) • Comorbidity management • OSA • CHF • Smoking cessation

  41. Home Oxygen Criteria • Indication • Pulmonary disorder (chronic) • Hypoxia related sign/symptoms • Tests (< 48hrs) • ABG • Pulse oximetry at rest or during exercise (6MWT) • Overnight oximetry (qualifies nocturnal O2 only) • Criteria

  42. Asthma: Step-up to more air BT/Nucala/Fasnera/Dupixent

  43. Overnight Oximetry : Clues to Identify

  44. Overnight Oximetry : Clues to Identify

  45. COPD/Asthma :Anxious for Breath • Role of anxiolytic for dyspnea • Benzo: No role, ?detrimental • Buspirone: Potential benefits w/o risks • Opioid: Palliative, risk vs ?benefit

  46. COPD: Infection vs Inflammation • Antibiotics for COPD • Exacerbation • Anti-inflammatory for LT management

  47. Thank You Imtiaz Ahmad, MD, FCCP Allergy Sleep & Lung Care 21st Century Oncology

  48. Supplementals

More Related